Data / Form D filings / Cellibre, Inc.
Cellibre, Inc.: Form D filings
Cellibre, Inc., a biotechnology company in San Diego, CA, filed 3 Form D notices with the SEC between 2019 and 2024. The latest, on October 9, 2024, reports $6.7 million sold of a $23.2 million offering to 31 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6825 FLANDERS DRIVE, San Diego, CA, 92121
- Phone
- (916) 539-5454
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1781232
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 9, 2024 | New notice | $23,215,672 | $6,707,314 | $16,508,358 | 31 | Sep 30, 2024 | sec.gov |
| Sep 8, 2021 | New notice | $15,000,000 | $9,873,243 | $5,126,757 | 35 | Aug 31, 2021 | sec.gov |
| Jul 1, 2019 | New notice | $5,000,000 | $4,188,000 | $812,000 | 21 | Jun 21, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Nicky Caiazza | Executive Officer, Director | |
| Scott Zingheim | Executive Officer, Director | |
| Spiros Kambourakis | Executive Officer, Director | |
| Benjamin Chiarelli | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Oct 7, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cellibre, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.